Are Scope 3 emissions mandatory to report for pharmaceutical companies?

For most large pharmaceutical companies, reporting Scope 3 emissions is becoming mandatory rather than optional. Regulations such as the EU’s Corporate Sustainability Reporting Directive (CSRD) now require many organizations to disclose their full value chain emissions, which include Scope 3. Whether your company falls under a reporting obligation depends on your size, location, and the markets you operate in. This article unpacks the key questions pharmaceutical companies are asking about Scope 3 in 2026.

Which regulations require pharmaceutical companies to report Scope 3 emissions?

The EU’s Corporate Sustainability Reporting Directive (CSRD) is currently the most significant driver of mandatory Scope 3 reporting for pharmaceutical companies. Large companies meeting certain size thresholds and listed EU companies are required to report on their full emissions footprint, including Scope 3, under the European Sustainability Reporting Standards (ESRS). Beyond the EU, the SEC’s climate disclosure rules in the United States and the UK’s Sustainability Disclosure Requirements are driving similar expectations globally.

For pharmaceutical companies specifically, the pressure is compounded by investor expectations and procurement requirements. Many large hospital networks and public health buyers now request emissions transparency as part of their supplier qualification process. Even companies that do not yet fall under a mandatory framework are increasingly expected to report voluntarily to remain competitive in tenders and partnerships.

The scope and timeline of these obligations vary. Under CSRD, phased implementation means that smaller companies are being brought into scope progressively through 2026 and beyond. Pharmaceutical companies operating internationally should assess their obligations under each jurisdiction where they operate, not just their home country.

What counts as a Scope 3 emission in the pharmaceutical supply chain?

Scope 3 emissions are all indirect greenhouse gas emissions that occur in a company’s value chain but outside its own operations. In the pharmaceutical supply chain, this covers a wide range of activities both upstream and downstream from the company itself.

Upstream Scope 3 sources in pharma typically include:

• The production and transportation of raw materials and active pharmaceutical ingredients (APIs)
• Packaging manufacturing, including the production of plastic components such as single-use electronic data loggers used in cold chain transport
• Business travel and employee commuting
• Capital goods procurement

Downstream Scope 3 sources include:

• The transportation and distribution of finished products to wholesalers, hospitals, and pharmacies
• Waste generated from product use and disposal by end customers
• The end-of-life treatment of products and packaging

Cold chain logistics is a particularly significant source of Scope 3 emissions for pharmaceutical companies. Temperature-controlled shipments rely heavily on single-use monitoring equipment, refrigerated vehicles, and energy-intensive storage. Each of these contributes to the overall Scope 3 footprint. The disposal of electronic data loggers, for example, represents a measurable source of emissions that many companies are only beginning to quantify.

What happens if a pharmaceutical company does not report Scope 3 emissions?

Pharmaceutical companies that fail to report Scope 3 emissions when required face a combination of regulatory, commercial, and reputational consequences. Under frameworks like CSRD, non-compliance can result in financial penalties and mandatory corrective disclosures. Regulators in the EU are actively building enforcement mechanisms, and auditors are increasingly required to verify sustainability reports alongside financial statements.

Beyond formal penalties, the commercial risks are growing just as quickly. Institutional investors, ESG rating agencies, and large procurement bodies use emissions data to assess supplier risk. A pharmaceutical company that cannot demonstrate progress on Scope 3 may find itself excluded from tenders, downgraded in ESG rankings, or deprioritized by investors with sustainability mandates.

Reputational exposure is also real. As public awareness of supply chain emissions increases, companies that are visibly absent from sustainability disclosures attract scrutiny. In a sector where trust is foundational, that scrutiny carries weight.

How can pharmaceutical companies start measuring their Scope 3 emissions?

Pharmaceutical companies can begin measuring their Scope 3 emissions by following the GHG Protocol’s Corporate Value Chain (Scope 3) Standard, which provides a structured methodology for identifying, categorizing, and calculating value chain emissions across 15 defined categories. The process does not need to be perfect from day one. Starting with the highest-impact categories and building from there is a widely accepted approach.

Practical steps to get started include:

1. Map your value chain: Identify all significant upstream and downstream activities, from raw material sourcing to product disposal.
2. Prioritize high-impact categories: For pharma, transportation and distribution, purchased goods, and waste are often the largest contributors.
3. Collect supplier data: Request emissions data from key suppliers and logistics partners. Where primary data is unavailable, use industry-average emission factors as a starting point.
4. Choose a reporting framework: Align your methodology with ESRS, CDP, or the GHG Protocol to ensure your data is comparable and audit-ready.
5. Set a baseline and track progress: Establishing a baseline year allows you to measure reduction efforts meaningfully over time.

One area where pharmaceutical companies often find quick wins is in cold chain logistics. Switching from single-use electronic data loggers, which require e-waste disposal, to more sustainable alternatives reduces the emissions associated with packaging and waste disposal. Electronic data loggers require dedicated e-waste streams, while paper-based loggers can be recycled through standard paper waste streams globally, making the emissions footprint far easier to account for and reduce.

How Tapp supports pharmaceutical Scope 3 reduction

Cold chain monitoring is one of the most overlooked contributors to pharmaceutical Scope 3 emissions, and it is also one of the most actionable. As the only provider of paper-based data loggers, Tapp has developed a monitoring solution that directly addresses the waste and emissions generated by traditional electronic loggers in pharmaceutical shipments.

Here is how paper-based data loggers make a measurable difference:

• No e-waste: Paper-based loggers are recyclable through standard paper waste streams globally, unlike electronic loggers that require dedicated e-waste disposal.
• Lithium-free design: The battery used in paper-based loggers contains no lithium, reducing the environmental impact of both production and disposal compared to single-use plastic alternatives.
• No app or hardware required: Any NFC-enabled smartphone reads the logger instantly, eliminating the need for USB infrastructure and removing a significant pain point for pharmaceutical companies with strict IT security policies.
• Automatic cloud upload: When a label is tapped, data is automatically uploaded to the cloud, giving both sender and receiver access to a complete temperature report without manual data retrieval.
• Quantifiable footprint reduction: Switching to paper-based loggers gives sustainability teams a concrete, reportable action that reduces Scope 3 emissions from packaging and waste categories.

If your pharmaceutical company is working to measure and reduce its Scope 3 footprint, cold chain monitoring is a practical place to start. Get in touch with Tapp to find out how paper-based data loggers can support your sustainability reporting.